Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

• Status: Completed
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: Pfizer
• Treatments: Maraviroc

Criteria

Inclusion Criteria:

• Asymptomatic HIV-1 infected male and female patients

• Weight between 50 and 100kg and within the permitted range for their height

• Patients with virus that targets CCR5 receptor

Exclusion Criteria:

• Patients with a CD4 count <250 cells/mm3 or HIV viral load <5000 copies/mL

• Patients whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion

• Patients with acquired immunodeficiency syndrome (AIDS) or a previous AIDS diagnosis

• Patients who are taking or have taken antiretroviral drugs in the eight weeks prior to the study screening visit